Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Everest Medicines
Biotech
Travere scales Everest with $1.1B deal for BTK inhibitor
Travere has set its sights on Everest's therapy for rare kidney diseases, paying $112.5 million upfront for a drug that has already begun the trek into the clinic.
Will Maddox
Jun 2, 2026 10:30am
Everest to continue mRNA ascent alone, ending Providence collab
Feb 20, 2024 8:19am
Inventiva, Kezar sell Asian rights to NASH and autoimmune assets
Sep 21, 2023 9:00am
Maxwell Biosciences taps 3 leaders—Chutes & Ladders
Sep 23, 2022 9:30am
Everest appoints Gilead, COVID therapy vet as CEO
Sep 19, 2022 11:58am
Blanchard bolts from Everest, resigning as CEO
Aug 26, 2022 6:14am
